Clinical and Molecular Characterisation of Orofaciodigital Syndromes and Other Clinical Phenotypes Secondary to Mutations in the OFD1 Gene

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2013 by Centre Hospitalier Universitaire Dijon
Sponsor:
Information provided by (Responsible Party):
Centre Hospitalier Universitaire Dijon
ClinicalTrials.gov Identifier:
NCT01962129
First received: October 8, 2013
Last updated: October 10, 2013
Last verified: October 2013
  Purpose

The aim of this multicentre study will be to better describe the clinical characteristics and the etiological bases of patients with OFD syndrome by identifying new genes involved in OFD syndrome. These results will make it possible, from patients who have been clearly identified from a clinical, cytogenetic and molecular point of view, to determine a study strategy in such patients. The data obtained will be used to guide clinical geneticists in genetic counselling for patients and their families.

Identification of the molecular bases of the different OFD syndromes will make it possible to determine whether or not they belong to the group of ciliopathies like type I OFD and to understand their physiopathological bases.

This study will also make it possible to better characterise the phenotype of boys with syndromic mental retardation related to the OFD1 gene and thus to define the clinical criteria of the study of this gene in boys with mental retardation.

The complete absence of knowledge concerning the genetic bases of OFD syndromes, apart from type I, the presence of a large collection of samples from patients with OFD syndrome at Dijon CHU, the recognition of the diagnostic laboratory for syndromic OFD at the international level as well as the technical platform and expertise in molecular cytogenetic methods including CGH-array and molecular genetics (sequencing, quantitative PCR, fragment analysis) at the Cytogenetics and Molecular Biology laboratories at Dijon CHU justify the implementation of such a study in 2010.


Condition Intervention
Orofaciodigital Syndromes
Biological: Sampling of blood

Study Type: Observational
Study Design: Observational Model: Case-Only
Official Title: Clinical and Molecular Characterisation of Orofaciodigital Syndromes and Other Clinical Phenotypes Secondary to Mutations in the OFD1 Gene

Resource links provided by NLM:


Further study details as provided by Centre Hospitalier Universitaire Dijon:

Primary Outcome Measures:
  • Blood Samples [ Time Frame: baselines ] [ Designated as safety issue: No ]

Estimated Enrollment: 133
Study Start Date: June 2011
Estimated Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Patients affected by a syndrome OFD Biological: Sampling of blood
Patients AFFECTED BY A SEVERE MENTAL RETARDATION SYNDROMIQUE Biological: Sampling of blood

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Orofaciodigital Syndromes type I, type VII or other orofaciodigital syndromes

Criteria

Inclusion Criteria:

Group 1: Study the molecular bases of OFD syndromes Patients from whom samples have been collected - declaration to the Ministry in progress Patients with an OFD syndrome with samples in the collection DC-2009-1045 and for which the declaration to the Ministry is in progress, will be included in this study. Indeed, the blood samples of 65 patients have been sent to us since 2002 for the study of the OFD l gene thanks to national and international recruitment: 35 presented clinical signs more or less associated with a mode of transmission suggesting OFD l syndrome and 30 presented other forms of OFD (OFDII, OFDVI, OFDVII, OFDVIII and OFDIX) or a polymalformative syndrome with OFD involvement (OFD+). We therefore constituted a second collection of DNA samples from 33 patients with OFD syndrome or a polymalformative syndrome with OFD involvement, who presented neither a mutation nor a rearrangement of the OFD1 gene.

The clinical data are already available from Doctor Christel Thauvin-Robinet, who is responsible for this collection. These patients have signed a non-opposition form allowing the use of their blood samples for research on OFD syndromes. These patients will therefore be included in this new study without the need for new consent. Only an information letter will be sent to them (annexe 4A)

Newly-included patients The inclusion criteria for patients are principally clinical and/or paraclinical, based on the clinical investigation usually conducted in the follow-up of these patients. Every index case must present an OFD syndrome with normal results for the study of the OFD1 gene by direct sequencing of genomic DNA and a search for major rearrangements using quantitative PCR. The index cases could be children (from birth onwards) or adults, male or female with sporadic or familial syndromes.

Patients will be recruited by the clinical investigators of this study. These patients could be:

  • patients already known by the investigator, who will contact the patient to invite them to take part in the research,
  • or new patients seen during a consultation in the first year of the study (inclusion period) The clinical dossier that accompanies each sample will include a case report form, a family tree, photographs of the patient a signed written informed consent form Symptomatic and asymptomatic relatives may also be included in our study, once their written informed consent has been provided, so as to exclude polymorphism using CGH-array or molecular biology, or to confirm the segregation of a mutation.

Minors will only be included in our study if they are symptomatic. All of those who take part in this research, whether they are patients or healthy or asymptomatic relatives have to be covered by a national health insurance agency.

Group 2: Study of the form of syndromic X-linked mental retardation secondary to mutations in the OFD1 gene Preexisting patient cohorts

Two different types of populations could be included:

  • Boys with Joubert syndrome with cerebellar hypoplasia at the origin of the "molar tooth" sign on cerebral MRI and a negative result for mutations in the genes involved in Joubert syndrome as described by Doctor Burglen (Hospital Trousseau, APHP)
  • Boys with a phenotype that could be linked to mutations in the OFD1 gene:

    • A cohort of boys with polydactyly+/- juvenile retinitis pigmentosa or obesity who were screened negative for BBS gene mutations recruited through Professor Dollfus (CHU Strasbourg)
    • A cohort of males with severe macrocephaly (>+4SD) with negative screening for mutations in the GPC3 gene recruited through Doctor Rossignol (CHU Trousseau, Paris) and Doctor Raynaud (CHU Tours).
    • A cohort of males with recurrent pulmonary infections, macrocephaly (>+4SD) and negative screening for mutations in the MECP2 gene recruited through Doctor Philippe (CHU Nancy), Doctor Badens (CHU Marseille), Professor Bieth (CHU Toulouse) and Professor Touraine (CHU St Etienne).

The clinical dossier that accompanies each DNA sample will include a case report form, a family tree, photographs of the patient a signed written informed consent form

Newly-included patients The inclusion criteria for patients are principally clinical and/or paraclinical, based on the clinical investigation usually conducted in the follow-up of these patients. All of the index cases will be males who must present: (1) Joubert syndrome with normal results for the genes responsible for Joubert syndrome or (3) syndromic mental retardation more or less associated with polydactyly, obesity, macrocephaly, pigmentary retinopathy, recurrent infections and/or the "molar tooth" sign on cerebral MRI. Index cases could be infants (from birth onwards) or adults, sporadic or familial cases with a mode of transmission compatible with X-linked inheritance.

Patients will be recruited by the clinical investigators of this study. These patients could be:

  • patients already known by the investigator, who will contact the patient to invite them to take part in the research,
  • or new patients seen during a consultation in the first year of the study (inclusion period) The clinical dossier that accompanies each sample will include a case report form, a family tree, photographs of the patient a signed written informed consent form Symptomatic and asymptomatic relatives may also be included in our study, once their written informed consent has been provided, so as to exclude polymorphism using CGH-array or molecular biology, or to confirm the segregation of a mutation.

Minors will only be included in our study if they are symptomatic. All of those who take part in this research, whether they are patients or healthy or asymptomatic relatives have to be covered by a national health insurance agency.

Exclusion criteria:

Patients will be excluded from the study if the clinical data do not meet the criteria defined above.

Patients with OFD syndrome in whom sequencing of the exons or exon-intron junctions of the OFD1 gene of genomic DNA and the search for major rearrangements quantitative PCR identify a causal mutation will not be included in this study.

The following patients will also be excluded from the study:

  • those who do not wish to provide a blood sample,
  • those who have not provided written informed consent,
  • those without national health insurance,
  • those in custody following a legal or administrative decision.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01962129

Contacts
Contact: Christel Thauvin 03.80.29.53.13 christel.thauvin@chu-dijon.fr

Locations
France
CHU Dijon Recruiting
Dijon, France, 21000
Contact: Christel Thauvin    03.80.29.53.13    christel.thauvin@chu-dijon.fr   
Sponsors and Collaborators
Centre Hospitalier Universitaire Dijon
  More Information

No publications provided

Responsible Party: Centre Hospitalier Universitaire Dijon
ClinicalTrials.gov Identifier: NCT01962129     History of Changes
Other Study ID Numbers: Thauvin PHRC N 2010
Study First Received: October 8, 2013
Last Updated: October 10, 2013
Health Authority: France: Agence Nationale de Sécurité du Médicament et des produits de santé

Additional relevant MeSH terms:
Craniofacial Abnormalities
Syndrome
Orofaciodigital Syndromes
Disease
Pathologic Processes
Dysostoses
Bone Diseases, Developmental
Bone Diseases
Musculoskeletal Diseases
Musculoskeletal Abnormalities
Abnormalities, Multiple
Congenital Abnormalities
Sex Chromosome Disorders
Chromosome Disorders
Genetic Diseases, Inborn

ClinicalTrials.gov processed this record on October 19, 2014